XML 46 R39.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Reporting - Schedule of Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue    
Collaboration and license revenue $ 982 $ 2,171
Operating expenses:    
Research and development 21,904 29,788
General and administrative 8,217 8,633
Other (expense) income:    
Interest and other income, net 1,162 2,802
Interest expense (689) (679)
Net loss (28,666) (34,127)
Reportable Segment    
Revenue    
Collaboration and license revenue 982 2,171
Other (expense) income:    
Interest and other income, net 1,162 2,802
Interest expense (689) (679)
Net loss (28,666) (34,127)
Reportable Segment | Laboratory Supplies, Research Materials and Studies    
Operating expenses:    
Research and development 4,278 9,489
Reportable Segment | Personnel Expenses    
Operating expenses:    
Research and development 8,331 8,816
General and administrative 3,517 3,019
Reportable Segment | Legal and Professional Fees    
Operating expenses:    
General and administrative 1,692 1,954
Reportable Segment | Facility-Related and Other    
Operating expenses:    
Research and development 1,690 1,808
General and administrative 4,565 5,548
Reportable Segment | Clinical Studies    
Operating expenses:    
Research and development 2,890 3,695
Reportable Segment | Stock-Based Compensation    
Operating expenses:    
Research and development 1,231 1,738
General and administrative 1,234 1,676
Reportable Segment | Depreciation Expense    
Operating expenses:    
Research and development 609 502
General and administrative $ 84 $ 176